MediWound Ltd (MDWD)

5.95
0.00 (0.00)
NASDAQ : Health Care
Prev Close 5.95
Open 5.95
Day Low/High 5.70 / 5.95
52 Wk Low/High 5.66 / 10.47
Volume 15.62K
Avg Volume 31.90K
Exchange NASDAQ
Shares Outstanding 21.87M
Market Cap 134.51M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

MediWound Reports Final Positive Results Of Phase 2 Clinical Trial Of EscharEx For The Debridement Of Chronic And Hard-to-Heal Wounds

MediWound Reports Final Positive Results Of Phase 2 Clinical Trial Of EscharEx For The Debridement Of Chronic And Hard-to-Heal Wounds

Data support previously reported positive top-line results; No significant safety concerns observed in the follow-up period

MediWound Granted U.S. Patent For MWPC003 For The Treatment Of Connective Tissue Diseases

MediWound Granted U.S. Patent For MWPC003 For The Treatment Of Connective Tissue Diseases

Further Protects Company's Proprietary Enzymatic Bromelain Solution

Mediwound is Now Oversold (MDWD)

Mediwound is Now Oversold (MDWD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

MediWound Reports Third Quarter 2016 Financial Results

MediWound Reports Third Quarter 2016 Financial Results

Conference call begins today at 8:30 a.m. Eastern time

Oversold Conditions For Mediwound (MDWD)

Oversold Conditions For Mediwound (MDWD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

MediWound's NexoBrid And EscharEx To Be Featured At International Society For Burn Injuries 2016

MediWound's NexoBrid And EscharEx To Be Featured At International Society For Burn Injuries 2016

Multiple oral and poster presentations highlight NexoBrid's and EscharEx' innovative, effective and fast enzymatic debriding of severe burns and chronic wounds

Mediwound Becomes Oversold (MDWD)

Mediwound Becomes Oversold (MDWD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

MediWound Reports Second Quarter 2016 Financial Results

MediWound Reports Second Quarter 2016 Financial Results

Conference call begins today at 8:30 a.m. Eastern time

MediWound's NexoBrid® To Be Highlighted In Presentations At The American Burn Association 48th Annual Meeting

MediWound's NexoBrid® To Be Highlighted In Presentations At The American Burn Association 48th Annual Meeting

11 Presentations Profile NexoBrid and the Benefits of Enzymatic Debridement

MediWound Reports First Quarter 2016 Financial Results

MediWound Reports First Quarter 2016 Financial Results

Conference call begins today at 8:30 a.m. Eastern time

This Isn't a Time to Be Too Clever

Sticking with momentum works much better than fighting it.

RSI Alert: Mediwound (MDWD) Now Oversold

RSI Alert: Mediwound (MDWD) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D (Sell)